Prevalence of candida africana among women with Vulvovaginal Candidiasis (VVC) and/or Bacterial Vaginosis (BV) in the United States

2017 ◽  
Vol 217 (6) ◽  
pp. 735-736 ◽  
Author(s):  
L.K. Rabe ◽  
J. Goldman ◽  
S. Bracken ◽  
J. Juul ◽  
L. Meyn ◽  
...  
2007 ◽  
Vol 34 (11) ◽  
pp. 864-869 ◽  
Author(s):  
Emilia H. Koumans ◽  
Maya Sternberg ◽  
Carol Bruce ◽  
Geraldine McQuillan ◽  
Juliette Kendrick ◽  
...  

2013 ◽  
Vol 121 (4) ◽  
pp. 773-780 ◽  
Author(s):  
Joelle M. Brown ◽  
Kristen L. Hess ◽  
Stephen Brown ◽  
Colleen Murphy ◽  
Ava Lena Waldman ◽  
...  

1995 ◽  
Vol 3 (4) ◽  
pp. 149-157 ◽  
Author(s):  
MerriKay A. Oleen-Burkey ◽  
Sharon L. Hillier

Objective: This study was undertaken to estimate the annual direct costs of complications associated with bacterial vaginosis (BV) in pregnant women in the United States.Methods: An economic model was developed from evidence in the published literature linking perinatal complications to BV. The estimates of attributable risks were applied to the estimated population of pregnant women in the United States in 1993. The charge data from a database of hospital utilization information were then used to estimate the direct costs of each pregnancy complication and the total direct costs associated with BV.Results: Under the assumptions of our model, the direct costs of preterm labor, preterm delivery, the attendant low birth weight (LBW), and other perinatal complications associated with BV were estimated at nearly $1.0 billion in 1993. Over 40% of the total cost was associated with preterm delivery and intensive care of LBW infants, while another 24.5% of the cost was related to preterm labor.Conclusions: If the current frequency of BV among pregnant women persists and BV is not detected and treated during pregnancy, the projected annual costs will reach $1.4 billion by the year 2000. Reducing the heavy economic burden associated with BV in pregnant women will require the establishment of effective screening and treatment regimens.


2011 ◽  
Vol 20 (10) ◽  
pp. 1497-1503 ◽  
Author(s):  
Audrey L. French ◽  
Oluwatoyin M. Adeyemi ◽  
Denis M. Agniel ◽  
Charlesnika T. Evans ◽  
Michael T. Yin ◽  
...  

2013 ◽  
Vol 17 (3) ◽  
pp. 340-345 ◽  
Author(s):  
Betsy Foxman ◽  
Ryan Muraglia ◽  
Jean-Paul Dietz ◽  
Jack D. Sobel ◽  
Julian Wagner

2014 ◽  
Vol 69 (Suppl 2) ◽  
pp. S205-S214 ◽  
Author(s):  
J. N. Hoffmann ◽  
H. M. You ◽  
E. C. Hedberg ◽  
J. A. Jordan ◽  
M. K. McClintock

Author(s):  
A. Hakam ◽  
J.T. Gau ◽  
M.L. Grove ◽  
B.A. Evans ◽  
M. Shuman ◽  
...  

Prostate adenocarcinoma is the most common malignant tumor of men in the United States and is the third leading cause of death in men. Despite attempts at early detection, there will be 244,000 new cases and 44,000 deaths from the disease in the United States in 1995. Therapeutic progress against this disease is hindered by an incomplete understanding of prostate epithelial cell biology, the availability of human tissues for in vitro experimentation, slow dissemination of information between prostate cancer research teams and the increasing pressure to “ stretch” research dollars at the same time staff reductions are occurring.To meet these challenges, we have used the correlative microscopy (CM) and client/server (C/S) computing to increase productivity while decreasing costs. Critical elements of our program are as follows:1) Establishing the Western Pennsylvania Genitourinary (GU) Tissue Bank which includes >100 prostates from patients with prostate adenocarcinoma as well as >20 normal prostates from transplant organ donors.


Sign in / Sign up

Export Citation Format

Share Document